Our open platform and strategic partnerships are enabling us to accelerate access to molecular detection across industry sectors and pathogen types.
“The partnership between Alveo and Black Diamond Ventures has been years in the making, fundamentally built on relationships and trust, a shared strategic vision, open lines of communication, and unwavering support for one another. I have personally known Chris and Ana for many years now, having co-invested together and with Black Diamond as a major investor in my prior company. Through their guidance over the years, coupled with continued investment support both directly and indirectly through introductions within their network, we have been able to overcome the many obstacles venture-backed companies traditionally face in the transition to a commercial organization, particularly in tough Life Sciences financing environments. Due in large part to BDV’s support, Alveo is now accelerating its growth, poised to achieve significant market traction in the near term. Together, we have not only created a solid foundation for Alveo but also set the stage for continued success and innovation in Alveo for years to come.” ~ Shaun Holt, CEO